A PHASE I STUDY OF SAVOLITINIB IN RECURRENT, PROGRESSIVE, OR REFRACTORY MEDULLOBLASTOMA, HIGH-GRADE GLIOMA, DIFFUSE INTRINSIC PONTINE GLIOMA, AND CNS TUMORS HARBORING MET ABERRATIONS

Registry ID

PBTC-049

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

PEDIATRIC BRAIN TUMOUR CONSORTIUM

Start date

2023-12-21

Completion date

2025-04-03

Last update

2022-10-04

Conditions

• GLIOMA
• MEDULLOBLASTOMA
• DIFFUSE INTRINSIC PONTINE GLIOMAS

Related clinical trials

• A PHASE II TRIAL OF ACT001 IN CHILDREN AND ADOLESCENTS WITH DIFFUSE INTRINSIC PONTINE GLIOMAS AND H3K27-ALTERED HIGH GRADE GLIOMAS
• A PHASE 3 STUDY OF SODIUM THIOSULFATE FOR REDUCTION OF CISPLATIN-INDUCED OTOTOXICITY IN CHILDREN WITH AVERAGE-RISK MEDULLOBLASTOMA AND REDUCED THERAPY IN CHILDREN WITH MEDULLOBLASTOMA WITH LOW-RISK FEATURES
• A PHASE 1/2 STUDY OF MIRDAMETINIB AND VINBLASTINE FOR NEWLY DIAGNOSED OR PREVIOUSLY UNTREATED PATIENTS WITH PEDIATRIC LOW-GRADE GLIOMA AND ACTIVATION OF THE MAPK PATHWAY
• A PHASE II STUDY EVALUATING THE SAFETY, EFFICACY, AND INTRACRANIAL ACTIVITY OF TARLATAMAB IN RECURRENT/REFRACTORY GLIOMAS WITH IDH MUTATION (TARGID)
• PHASE II TRIAL OF EFLORNITHINE/DFMO AS MAINTENANCE THERAPY FOR MOLECULAR HIGH RISK/VERY HIGH RISK AND RELAPSED/REFRACTORY MEDULLOBLASTOMA
• ASSESSMENT OF SAFETY AND FEASIBILITY OF FUS NEXT GENERATION DOME HELMET MEDIATED BLOOD-BRAIN BARRIER DISRUPTION FOR THE TREATMENT OF HIGH-GRADE GLIOMA IN PATIENTS UNDERGOING STANDARD CHEMOTHERAPY

View on source registry